Class II
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC, Grand Cayman, Cayman Islands, NDC 82009-032-10.
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
- Recall number
- D-0215-2026
- Report date
- December 10, 2025
- Classification
- Class II
- Status in dataset
- Ongoing
- Recalling firm
- Breckenridge Pharmaceutical, Inc.
- Generic names
- DULOXETINE HYDROCHLORIDE
- Brand names
- DULOXETINE
- Product NDCs
- 82009-029, 82009-030, 82009-032, 82009-031
Code and lot information
Lot #: 240947C, 240962C, Exp. Date 04/2027
Distribution
Nationwide within the United States
Do not stop or change a prescribed medication based only on this page.Contact your pharmacist or prescriber and compare the exact product, manufacturer, NDC, and lot information.
Source and limitations
This page reflects a public openFDA Drug Enforcement record. The dataset was last checked on September 23, 2026. openFDA states that enforcement data should not be used alone to issue public alerts or track the full lifecycle of a recall.
Review the official FDA Drug Recalls page and the underlying openFDA query.